Gilead Sciences Inc
MIL:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
MIL:GILD
Watchlist
Price: 68.88 EUR 1.09%
Market Cap: €85.9B

Net Margin

27.9%
Current
Improving
by 13%
vs 3-y average of 14.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
27.9%
=
Net Income
$8.1B
/
Revenue
$29.1B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
27.9%
=
Net Income
€8.1B
/
Revenue
$29.1B

Peer Comparison

Country Company Market Cap Net
Margin
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.2B EUR
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
112.1B USD
Loading...
US
Biogen Inc
NASDAQ:BIIB
25.8B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...

Market Distribution

Higher than 91% of companies in the United States of America
Percentile
91th
Based on 15 072 companies
91th percentile
27.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Gilead Sciences Inc
Glance View

Gilead Sciences Inc., established in 1987, embarked on its mission with a resolute focus on innovative therapeutic advancements. Nestled in the biotech haven of Foster City, California, Gilead pioneered a path that would see it evolve into a global biopharmaceutical powerhouse. The company’s nucleus is its commitment to discovering, developing, and delivering therapies for diseases with unmet medical needs. Its product portfolio reflects this dedication, notably dominated by groundbreaking advancements in antiviral therapies, particularly for HIV/AIDS, hepatitis B, and hepatitis C. Over the years, its robust research and development engine, fueled by a continual reinvestment of earnings, propelled it to the forefront of tackling complex medical challenges. Its strategic acquisitions, like the pivotal purchase of Pharmasset in 2011, underpinned its ascent in the hepatitis C treatment arena, highlighting its aptitude for identifying and integrating synergistic growth opportunities. Financially, Gilead generates its revenue through the commercialization of its pharmaceutical portfolio. It thrives on a model where its novel therapies, once developed and approved, are sold to healthcare providers and systems. The landscape of antiviral treatments, primarily the revolutionary HIV regimen and hepatitis C cures like Harvoni and Sovaldi, serves as the backbone of its revenue stream. Meanwhile, Gilead's ventures into oncology and inflammatory diseases through strategic acquisitions and partnerships aim to diversify its portfolio beyond infectious diseases. The intricate process from innovation to distribution underscores Gilead’s proficient use of its clinical expertise and market acumen to address both expanding global health needs and shareholder demands, ensuring its enduring presence in the volatile seas of the biotech industry.

GILD Intrinsic Value
66.31 EUR
Overvaluation 4%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
27.9%
=
Net Income
$8.1B
/
Revenue
$29.1B
What is Gilead Sciences Inc's current Net Margin?

The current Net Margin for Gilead Sciences Inc is 27.9%, which is above its 3-year median of 14.8%.

How has Net Margin changed over time?

Over the last 3 years, Gilead Sciences Inc’s Net Margin has increased from 12.3% to 27.9%. During this period, it reached a low of 0.4% on Sep 30, 2024 and a high of 27.9% on Sep 30, 2025.

Back to Top